Eligible adults typically have: A BMI 35 kg/m and at least one weight-related comorbidity, or A BMI between 3034.9 kg/m when meeting specialist referral criteria (lower thresholds may apply for some ethnic groups) When restarting after an extended break, healthcare providers should: Reassess the patient's current weight and comorbidities Review the reasons for treatment interruption Ensure contraindications have not developed during the break Discuss realistic expectations for weight loss trajectory Reinforce dietary and lifestyle modification strategies Patients should be counselled that restarting at the lowest dose is a safety measure, not a setback
Taking Ozempic, Wegovy, Mounjaro, or Zepbound doesn't mean giving up restaurants, social meals, or dining out for work or travel
Key takeaways Tirzepatide is the active ingredient in both Mounjaro and Zepbound, while semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus
In contrast, at least 1 of the folate receptors, FR-, is expressed in hematopoietic cells and the kidney proximal tubules, among other tissues (Table 2)
